About

iVIEW Therapeutics Inc. is a clinical stage biotechnology company focusing on innovative ophthalmic therapeutics. We are driven by the pursuit of innovative science that leads to differentiated products to fulfill unmet medical needs. We invest in novel mechanisms of action, and differentiated drug delivery technology platforms that allow us to bring forward assets with potentially superior target product profiles. The company's innovative eye drugs cover dry eye, myopia, conjunctivitis, presbyopia, and innovative gene therapy. IVIEW is located in Cranbury, New Jersey with 11,045 sq. fts. Laboratory and office space in the greater Princeton area.  

Our R&D in Cranbury campus is focused on the research and development of novel ophthalmic therapeutics to market. The company's innovative intellectual property covers drug candidates for the treatment of dry eye, myopia, conjunctivitis, presbyopia, and innovative gene therapy. IVW-1001 and IView-1201 are leading assets in the clinical development stages. IVW-1001 is a novel small molecule compound developed as a novel TRPM8 agonist to treat Dry Eye Disease. IView-1201 is a proprietary formulation of a broad-spectrum antiseptic developed for treatment for Acute Bacterial and Adenoviral Conjunctivitis, currently in global phase II trials.  

As an innovative pharmaceutical research and development company, IVIEW has not generated revenues from sales yet as our products are in the development stage without any approved products on the market.  We have received some income from ERC and selling NOL in prior years (from Pennsylvania before moving to New Jersey in 2021), however our operation is primarily funded by stockholders including investors.  

IVIEW has eleven full-time employees who each play an important and unique role in day-to-day operations.  Our full-time employees are mainly experienced pharmaceutical industry experts and scientists. Our CEO, Dr. Bo Liang is a serial entrepreneur and experienced drug discovery scientist. Not only does he manage the overall business for strategy, fund raising and operation, but also, he is the main inventor of many IPs of the company. Colin Walters, VP of Pharmaceutical Development, heads all the company’s development programs, including CMC development and project management. He has over 25 years' big pharma experiences in Merck, Schering, Celgene and BMS. Colin heads the formulation and CMC development group, which consists of two bright PhD scientists graduated from Rutgers University, and one associate scientist in our Cranbury laboratory. A series of innovative formulation IPs are generated from his group research. Colin also manages external partners in CMC, clinical, regulatory and business development. Dr. Laura Hong is Head of Innovation at the company, leading IVIEW’s innovative gene therapy program to treat Glaucoma. She has over 14 years of big molecule and vaccine development experiences at Merck and was US President at Klus Pharma prior joining IVIEW. She heads the Gene Therapy development group, which consists of a PhD Principal scientist and one experienced PhD scientist with over 6 years postdoc AAV gene therapy development experience at Princeton University. Working with Dr. Borras Terete, a professor Emeritus at UNC Chapel Hill, the Gene Therapy development group has developed 3 innovative IPs within a short period of time since the inception of the GT program in 2022. Zuliang Yao, MD and Wei Wang, PhD head the company’s pre-clinical and translation research. We also have one Executive assistant to support office, HR, accounting tasks by working with external firms.